Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Urokinase-Induced Fibrinolysis of Human Standard Clots

Abstract

STUDIES with human fibrinolysis, either induced by pyrogens or appearing during thoracic surgery, together with other observations, indicate that very likely the first phase of an endogenous fibrinolytic reaction in man is the release of a plasminogen activator from the tissues into the blood stream. The question whether this activator can induce lysis of an intravascular clot directly was studied in vitro with human urokinase, a plasminogen activator excreted with the urine, as the enzyme source and human standard clots as substrate.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. von Kaulla, K. N., Proc. Soc. Biol. and Exp. Med., 91, 543 (1956).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

VON KAULLA, K. Urokinase-Induced Fibrinolysis of Human Standard Clots. Nature 184, 1320–1321 (1959). https://doi.org/10.1038/1841320b0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/1841320b0

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing